• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    3/8/24 4:31:10 PM ET
    $ATRA
    $COCH
    $ESLA
    $FTRE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Specialties
    Health Care
    Get the next $ATRA alert in real time by email

    Gainers

    • Talphera (NASDAQ:TLPH) shares moved upwards by 15.6% to $1.3 during Friday's after-market session. The company's market cap stands at $22.0 million. As per the news, the Q4 earnings report came out 2 days ago.
    • Genelux (NASDAQ:GNLX) shares increased by 10.06% to $7.0. The market value of their outstanding shares is at $187.0 million.
    • Estrella Immunopharma (NASDAQ:ESLA) stock rose 8.65% to $1.13. The market value of their outstanding shares is at $41.3 million.
    • Inspire Veterinary (NASDAQ:IVP) stock increased by 8.5% to $0.06. The market value of their outstanding shares is at $1.6 million.
    • NRX Pharmaceuticals (NASDAQ:NRXP) shares moved upwards by 5.15% to $0.65. The market value of their outstanding shares is at $59.1 million.
    • Fortrea Holdings (NASDAQ:FTRE) shares rose 5.02% to $38.68. The company's market cap stands at $3.4 billion.

    Losers

    • Atara Biotherapeutics (NASDAQ:ATRA) shares decreased by 9.4% to $0.69 during Friday's after-market session. The market value of their outstanding shares is at $70.3 million.
    • ProKidney (NASDAQ:PROK) stock fell 7.51% to $1.54. The market value of their outstanding shares is at $104.5 million.
    • Mira Pharmaceuticals (NASDAQ:MIRA) stock declined by 7.01% to $1.46. The market value of their outstanding shares is at $21.5 million.
    • Yield10 Bioscience (NASDAQ:YTEN) shares fell 5.88% to $0.25. The company's market cap stands at $2.9 million.
    • GeneDx Hldgs (NASDAQ:WGS) shares fell 5.01% to $7.97. The company's market cap stands at $207.6 million.
    • Envoy Medical (NASDAQ:COCH) shares fell 5.0% to $8.55. The company's market cap stands at $167.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATRA
    $COCH
    $ESLA
    $FTRE

    CompanyDatePrice TargetRatingAnalyst
    Fortrea Holdings Inc.
    $FTRE
    3/9/2026$15.00Hold → Buy
    TD Cowen
    GeneDx Holdings Corp.
    $WGS
    2/9/2026$155.00Equal Weight → Overweight
    Wells Fargo
    Atara Biotherapeutics Inc.
    $ATRA
    1/13/2026$6.00Buy → Hold
    Canaccord Genuity
    Fortrea Holdings Inc.
    $FTRE
    1/8/2026$22.00Hold → Buy
    Truist
    Fortrea Holdings Inc.
    $FTRE
    1/6/2026$25.00In-line → Outperform
    Evercore ISI
    ProKidney Corp.
    $PROK
    12/16/2025$12.00Buy
    H.C. Wainwright
    Fortrea Holdings Inc.
    $FTRE
    12/15/2025$15.00Underweight → Equal Weight
    Barclays
    Fortrea Holdings Inc.
    $FTRE
    12/11/2025$21.00Neutral → Buy
    Citigroup
    More analyst ratings

    $ATRA
    $COCH
    $ESLA
    $FTRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

    WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. In addition to reviewing the Company's financial results for the fiscal year ended December 31, 2025, the Company will provide an update on the significant progress achieved across its drug development programs and the HOPE Therapeutics clinical network, milestones that bring the Company closer to its founding mission of preventing suicide and transforming the treatment of depression and PTSD to improve the lives of patient

    3/19/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026

    SAN MATEO, Calif., March 18, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a virtual investor and analyst event on Monday, March 23, 2026 at 11:00 AM ET featuring Blaithin McMahon, PhD, MBBChr (Medical University of South Carolina) and Joao Teixeira, MD (University of New Mexico), principal investigators in Talphera's NEPHRO CRRT study evaluating Niyad for continuous renal replacement therapy (CRRT). To register, click here.The experts will discuss their experience with CRRT, the anticoagulan

    3/18/26 4:05:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProKidney Reports Full Year 2025 Financial Results and Business Highlights

    On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027In a July 2025 Type B meeting, aligned with FDA on the accelerated approval pathway for rilparencel using eGFR slope as the surrogate endpointPresented positive results from the Phase 2 REGEN-007 study of rilparencel as a late-breaking clinical trial at ASN Kidney Week 2025 followed by a peer-reviewed publication in CJASNEnded 2025 with $270.0 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 WINSTON-SALEM, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("Pro

    3/18/26 4:00:00 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    $COCH
    $ESLA
    $FTRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fortrea upgraded by TD Cowen with a new price target

    TD Cowen upgraded Fortrea from Hold to Buy and set a new price target of $15.00

    3/9/26 8:42:40 AM ET
    $FTRE
    Medical Specialities
    Health Care

    GeneDx upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded GeneDx from Equal Weight to Overweight and set a new price target of $155.00

    2/9/26 6:58:22 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Atara Biotherapeutics downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Atara Biotherapeutics from Buy to Hold and set a new price target of $6.00

    1/13/26 10:16:38 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    $COCH
    $ESLA
    $FTRE
    SEC Filings

    View All

    SEC Form S-8 filed by ProKidney Corp.

    S-8 - PROKIDNEY CORP. (0001850270) (Filer)

    3/18/26 4:07:55 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ProKidney Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PROKIDNEY CORP. (0001850270) (Filer)

    3/18/26 4:03:55 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by ProKidney Corp.

    10-K - PROKIDNEY CORP. (0001850270) (Filer)

    3/18/26 4:01:34 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    $COCH
    $ESLA
    $FTRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Stueland Katherine sold $1,319,291 worth of shares (17,179 units at $76.80) and converted options into 30,671 shares, increasing direct ownership by 30% to 58,447 units (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/17/26 6:40:58 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 11,012 shares and sold $438,203 worth of shares (5,706 units at $76.80), increasing direct ownership by 24% to 27,148 units (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/17/26 6:39:59 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    SEC Form 4 filed by Large owner Nantahala Capital Management, Llc

    4 - TALPHERA, INC. (0001427925) (Issuer)

    3/17/26 4:30:38 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATRA
    $COCH
    $ESLA
    $FTRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Meister Keith A. bought $13,460,090 worth of shares (169,521 units at $79.40) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/5/26 7:19:34 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    CHIEF EXECUTIVE OFFICER Angotti Vincent J. covered exercise/tax liability with 12,738 shares and bought $85,587 worth of shares (105,364 units at $0.81), increasing direct ownership by 19% to 577,395 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/20/26 8:28:48 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Aslam Shakil bought $28,430 worth of shares (35,000 units at $0.81), increasing direct ownership by 73% to 83,178 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/20/26 8:27:03 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATRA
    $COCH
    $ESLA
    $FTRE
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Air Transport Services Group Inc on Jun 7 Indicate?

    Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were

    6/10/24 12:35:45 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATRA
    $COCH
    $ESLA
    $FTRE
    Leadership Updates

    Live Leadership Updates

    View All

    NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

    Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the science of neuroplasticity and its relationship to healing depression and PTSD.Unique background in charting a path for forward deployment of TMS with neuroplastic medication to treat depression and PTSD in military personnel, veterans, and first responders. WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, MD, P

    3/2/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care

    Recognized neonatologist and payer-strategy leader joins GeneDx to expand earlier diagnosis and establish genomics as a standard of care across healthcare GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights today announced Linda Genen, MD, MPH as Chief Medical Officer to further strengthen the company's commitment to delivering earlier answers and better outcomes for families through genomic insights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106493899/en/GeneDx Names Dr. Linda Genen, MD, MPH as Chief Medical Officer In her role at GeneDx, Dr. Genen will oversee Medical and Cli

    1/6/26 8:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

    WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) --  Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones. "We are excited to welcome Jason, who is widely recognized for his strategic approach to clinical development and commitment to improving patient outcomes," said Thomas Zindrick, President, CEO, and Chairman of the Board. "He brings extensive experience in oncology drug development of innovati

    1/2/26 8:00:00 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATRA
    $COCH
    $ESLA
    $FTRE
    Financials

    Live finance-specific insights

    View All

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

    WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. In addition to reviewing the Company's financial results for the fiscal year ended December 31, 2025, the Company will provide an update on the significant progress achieved across its drug development programs and the HOPE Therapeutics clinical network, milestones that bring the Company closer to its founding mission of preventing suicide and transforming the treatment of depression and PTSD to improve the lives of patient

    3/19/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial

    Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sitesCompany to host a virtual investor and analyst event on March 23 at 11:00 am ET featuring nephrologists, Dr. Blaithin McMahon and Dr. Joao TeixeiraSAN MATEO, Calif., March 2, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced 50% patient enrollment of the NEPHRO-CRRT clinical trial."Over the course of 2025, with agreement from the FDA, we implemented significant changes to the NEPHRO CRRT clinical tr

    3/2/26 8:30:00 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance

    Revenue and Adjusted EBITDA results delivered in line with stated full-year targetsFull‑year cost savings exceeded previously communicated targets Highlights: Revenues of $660.5 million for the fourth quarter and $2,723.4 million for the full yearFourth-quarter book-to-bill ratio of 1.14x, resulting in 1.02x book-to-bill for the trailing 12 monthsGAAP net loss of $(32.5) million, or $(0.35) per diluted share for the fourth quarter; $(986.2) million, or $(10.81) per diluted share for the full yearAdjusted EBITDA of $54.0 million for the fourth quarter and $189.9 million for the full yearAdjusted net income of $9.2 million, or $0.09 per diluted share for the fourth quarter; $40.4 million, or

    2/26/26 6:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $ATRA
    $COCH
    $ESLA
    $FTRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/20/24 9:36:13 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/19/24 8:00:24 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

    SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

    11/14/24 6:10:20 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care